Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
One of the problems with prostate cancer is that it can take many years for the disease to develop from a very small group of cells in a man’s prostate into a disorder that has actual clinical significance.
Filed under: Diagnosis, Risk | Tagged: clinically significant, early stage, ethics, Malmo, prognosis, trial | Leave a Comment »
Based on the 14 to 2 “against” vote of an Oncology Drugs Advisory Committee meeting late last year, the U.S. Food & Drug Administration has rejected the application to approve dutasteride (Avodart) for prevention of prostate cancer in men at potentially elevated risk for a future postive biopsy.
Filed under: Drugs in development, Prevention | Tagged: dutasteride, FDA, Prevention | 5 Comments »
About 7 months ago we commented on an Italian study of the association between perineural invasion (PNI) on biopsy and outcomes after first-line surgical treatment for localized prostate cancer.
Filed under: Diagnosis, Management, Risk, Treatment, Uncategorized | Tagged: perineural invasion, PNI, prognosis, risk | Leave a Comment »
The idea that having good policies and procedures in place to help patients and family members to address end-of-life care is highly controversial in some quarters. However, The “New” Prostate Cancer InfoLink believes that there is a great need for clear professional and consumer guidance on end-of-life care related to cancer …
Filed under: Living with Prostate Cancer, Management | Tagged: care, end of life, hospice, palliation | 1 Comment »
A regular reader of this column asked us to provide a “layman’s summary” of how the investigational drug abiraterone acetate actually works to delay the progression of metastatic, castration-resistant prostate cancer (mCRPC). So here you go
Filed under: Management, Treatment, Uncategorized | Tagged: abiraterone, action, mechanism | 9 Comments »
The collaborative research between the teams at Memorial Sloan-Kettering Cancer Center in New York and in Malmö in Sweden continues to refine a model that may allow us to accurately predict which patients are at clinically significant risk for prostate cancer based solely on simple tests run on a single blood sample.
Filed under: Diagnosis, Risk, Uncategorized | Tagged: biopsy, clinically significant, kallikrein, prediction, PSA, risk | Leave a Comment »
A clear appreciation of the associations between life expectancy, comorbid conditions (e.g., diabetes, obesity, cardiovascular disorders), and mortality is critically important to treatment decisions for all patients with prostate cancer, but most especially the newly diagnosed, low-risk patient.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: comorbidity, outcome, survival, Sweden, Treatment | Leave a Comment »
High-intensity focused ultrasound (HIFU) is approved in Canada for the treatment of localized prostate cancer. Since its approval, this form of treatment has become popular among patients seeking a potentially curative form of treatment with low risk for complications and side effects.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: failure, HIFU, high-intensity focuse ultrasound, outcome, salvage, surgery | Leave a Comment »
The Surgical Prostatectomy versus Interstitial Radiation Intervention Trial or SPIRIT was a Phase III, partially randomized clinical trial, conducted in the U.S.A. and Canada, and designed to compare radical prostatectomy (RP) and brachytherapy (BT) as first-line treatments for men with localized prostate cancer.
Filed under: Management, Treatment | Tagged: brachytherapy, HRQOL, localized, outcome, quality of life, radical prostatectomy, SPIRIT | Leave a Comment »
Sometimes we all struggle to try and understand what we are looking at. Here’s a sentence from a paper we have just been reading: “After transduction of myristolated-AKT (a serine/threonine protein kinase) and ERG (an ets family transcription factor), lesions resembling [PIN] … developed.”
Filed under: Uncategorized | Tagged: origin, stem cell, theory | Leave a Comment »
According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana)
Filed under: Drugs in development, Management, Treatment | Tagged: approval, cabazitaxel, EMEA, Europe, Jevtana | Leave a Comment »
For several years we have been able to use the Kattan nomograms to project 5-, 7-, and 10-year recurrence-free survival before and after radical prostatectomy for localized prostate cancer, based on the patient’s age, stage, Gleason score, and other relevant data (associated with biopsy or surgical findings, as appropriate).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: 15-year, Kattan, mortality, nomogram, PCSM, prediction, projection, prostate cancer-specific, radical prostatectomy, surgery | 36 Comments »
It is unlikely to come as any big surprise to the average prostate cancer patient who was potent before first-line therapy but has erectile dysfunction (ED) afterward that there might be an association between ED and depression after initial treatment for localized prostate cancer.
Filed under: Living with Prostate Cancer | Tagged: depression, ED, erectile dysfunction | 6 Comments »
There has long been discussion about the appropriate and inappropriate uses of androgen deprivation therapy (ADT) in the management of progressive prostate cancer. The “New” Prostate Cancer InfoLink has regularly commented on the inherent dangers of using ADT to “manage PSA levels” as opposed to managing a patient’s actual clinical condition.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, therapy, timing | 9 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site